Features of humoral immune response in acute post-viral rhinosinusitis in former measles patients
- Authors: Kornova N.V.1, Gizinger O.A.2, Gaziev A.R.2, Zyrianova K.S.1, Beloshangin A.S.1
-
Affiliations:
- South Ural State Medical University
- P. Lumumba Peoples’ Friendship University
- Issue: Vol 28, No 3 (2025)
- Pages: 725-730
- Section: SHORT COMMUNICATIONS
- URL: https://journal-vniispk.ru/1028-7221/article/view/319925
- DOI: https://doi.org/10.46235/1028-7221-17115-FOH
- ID: 319925
Cite item
Full Text
Abstract
Measles, a highly contagious acute viral disease, transmitted by airborne droplets, is a leader among infectious diseases, both in terms of the incidence, and common complications affecting different organs and systems. According to WHO data of 2024, more than 17.3 million cases of measles were reported worldwide, and Russian Federation reported on more than 18,977 cases over the past year, according to Rospotrebnadzor data, and this number is continuously growing. The reported features of this disease over the winter-to-autumn epidemiological season 2024 include pronounced immune disorders and complications from the upper respiratory tract. Our aim was to assess the state of humoral immune response factors in acute post-viral rhinosinusitis in the persons who suffered measles. A prospective, open-label clinical trial was conducted. The level of measles-specific antibodies was studied by the content of IgG and IgM in blood serum of persons aged 19 to 55 years. Statistical data were collected, and the study was carried out at Hemotest LLC Laboratory, the Consulting and Diagnostic Center at the P. Lumumba Peoples’ Friendship University of Russia (RUDN University, Moscow, Russia). The ELISA technique with Vector-Best test systems (Novosibirsk, Russia) were used to determine specific IgG and IdM in blood serum. The cytokine concentrations in nasal mucosa were determined using the ELISA method. In patients with acute post-measles rhinosinusitis, high serum concentrations of specific IgM antibodies were found in 25% of these cases, and high concentrations of IgG, in 75% of patients. In presence of acute rhinosinusitis, measles patients showed a 3.1-fold decrease in secretory IgA in nasal secretions against healthy controls, along with 2.35-fold increase in serum IL-1b, and 3.17-fold increase in IL-6, TNFα, IL-10, and IL-8 elevation was 3.78 times, 1.96 times, and 9.15 times respectively, thus suggesting an imbalance of inflammation regulatory molecules and inflammatory process in nasal cavity and paranasal sinuses. Acute rhinosinusitis is one of the frequent complications in paramyxovirus infection. Its specific features presume an immunological imbalance, manifesting as increased production of pro-inflammatory cytokines and decrease in IgG, IgA, and sIgA.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Natalya Viktorovna Kornova
South Ural State Medical University
Author for correspondence.
Email: korkmazov74@gmail.com
PhD (Medicine), Associate Professor, Department of Otorhinolaryngology
Russian Federation, ChelyabinskO. A. Gizinger
P. Lumumba Peoples’ Friendship University
Email: Korkmazov74@gmail.com
PhD, MD (Biology), Associate Professor, Professor of Higher Attestation Commission, Department of Immunology and Allergology, Medical Institute
Russian Federation, MoscowA. R. Gaziev
P. Lumumba Peoples’ Friendship University
Email: korkmazov74@gmail.com
Student, Medical Institute
Russian Federation, MoscowK. S. Zyrianova
South Ural State Medical University
Email: korkmazov74@gmail.com
PhD (Medicine), Associate Professor, Department of Otorhinolaryngology
Russian Federation, ChelyabinskA. S. Beloshangin
South Ural State Medical University
Email: korkmazov74@gmail.com
PhD (Medicine), Associate Professor Department of Otorhinolaryngology
Russian Federation, ChelyabinskReferences
- Гуров А.В., Юшкина М.А., Мужичкова А.В. Поствирусный риносинусит, фокус на патогенетическую терапию // Вестник оториноларингологии, 2023. Т. 88, № 3. С. 38-43. [Gurov A.V., Yushkina M.A., Muzhichkova A.V. Post-viral rhinosinusitis, focus on pathogenetic therapy. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology, 2023, Vol. 88, no. 3, pp. 38-43. (In Russ.)]
- Дубинец И.Д., Синицкий А.И., Коркмазов М.Ю., Черных Е.И., Кухтик С.Ю. Окислительная модификация белков ткани височной кости при хронических средних отитах // Казанский медицинский журнал., 2019. Т. 100, № 2. С. 226-231. [Dubinets I.D., Sinitsky A.I., Korkmazov M.Yu., Chernykh E.I., Kuhtik S.Yu. Oxidative modification of temporal bone tissue proteins in chronic otitis media. Kazanskiy meditsinskiy zhurnal = Kazan Medical Journal, 2019, Vol. 100, no. 2, pp. 226-231. (In Russ.)]
- Коркмазов М.Ю., Корнова Н.В., Ленгина М.А., Смирнов А.А., Коркмазов А.М., Дубинец И.Д. Эффективная антибактериальная терапия внебольничной оториноларингологической респираторной инфекции (клиническое описание) // Медицинский совет, 2022. № 20. С. 73-81. [Korkmazov M.Yu., Kornova N.V., Lengina M.A., Smirnov A.A., Korkmazov A.M., Dubinets I.D. Effective antibiotic therapy for community-acquired otorhinolaryngological respiratory infection (clinical description). Meditsinskiy sovet = Medical Council, 2022, no. 20, pp. 73-81. (In Russ.)]
- Коркмазов М.Ю., Ленгина М.А., Коркмазов А.М., Кравченко А.Ю. Влияние постковидного синдрома на качество жизни пациентов с аллергическим ринитом и эозинофильным фенотипом хронического полипозного риносинусита // Российский медицинский журнал, 2023. Т. 29, № 4. C. 277-290. [Korkmazov M.Y u., Lengina M.A., Korkmazov A.M., Kravchenko A.Y. Effect of post-COVID syndrome on the quality of life of patients with allergic rhinitis and eosinophilic phenotype of chronic polyposis rhinosinusitis. Rossiyskiy meditsinskiy zhurnal = Medical Journal of the Russian Federation, 2023, Vol. 29, no. 4, pp. 277-290. (In Russ.)]
- Коркмазов М.Ю., Зырянова К.С., Белошангин А.С. Оценка клинической эффективности фитотерапевтического лекарственного препарата в лечении и профилактике рецидивов острых риносинуситов у детей г. Челябинска // Медицинский совет, 2016. № 7. С. 90-93. [Korkmazov M.Yu., Zyryanova K.S., Beloshangin A.S. Evaluation of the clinical efficacy of a phytotherapeutic drug in the treatment and prevention of recurring acute rhinosinusitis in children of Chelyabinsk. Meditsinskiy sovet = Medical Council, 2016, no. 7, pp. 90- 93. (In Russ.)]
- Коркмазов М.Ю. Биорезонанс. Основные принципы биорезонансной и электромагнитной терапии // Вестник оториноларингологии, 2008. № 2. С. 59-61. Korkmazov M.Yu. Bioresonance. Main principles of bioresonance and electromagnetic therapy. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology, 2008, no. 2, pp. 59-61. (In Russ.)
- Коркмазов М.Ю., Ленгина М.А., Коркмазов А.М., Корнова Н.В., Белошангин А.С. Лечение и профилактика различных форм ларингита на фоне острых респираторных инфекций // Медицинский совет, 2022. Т. 16, № 8. С. 79-87. [Korkmazov M.Yu., Lengina M.A., Korkmazov А.M., Kornova N.V., Beloshangin А.S. Treatment and prevention of various forms of laryngitis on the background of acute respiratory infections. Meditsinskiy sovet = Medical Council, 2022, Vol. 16, no. 8, pp. 79-87. (In Russ.)]
- Коркмазов М.Ю., Ястремский А.П., Корнова Н.В., Ленгина М.А., Коркмазов А.М. Лечебно-диагностические подходы в терапии хронического тонзиллита // Медицинский совет, 2022. Т. 16, № 20. С. 90-99. [Korkmazov M.Yu., Yastremsky A.P., Kornova N.V., Lengina M.A., Korkmazov A.M. Therapeutic and diagnostic approaches in the treatment of chronic tonsillitis. Meditsinskiy sovet = Medical Council, 2022, Vol. 16, no. 20, pp. 90-99. (In Russ.)]
- Коркмазов М.Ю., Крюков А.И., Дубинец И.Д., Тюхайз М.В., Учаев А.А., Маркелов А.В. Классификация структурных изменений костной ткани при хроническом гнойном среднем отите // Вестник оториноларингологии, 2019. Т. 84, № 1. С. 12-17. [Korkmazov M.Yu., Kryukov A.I., Dubinets I.D., Tyukhai M.V., Uchaev A.A., Markelov A.V. Classification of structural changes in bone tissue in chronic purulent otitis media. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology, 2019, Vol. 84, no. 1, pp. 12-17. (In Russ.)]
- Коркмазов М.Ю., Казачков Е.Л., Ленгина М.А., Дубинец И.Д., Коркмазов А.М. Причинно-следственные факторы развития полипозного риносинусита // Российская ринология, 2023. Т. 31, № 2. С. 124-130. [Korkmazov M.Yu., Kazachkov E.L., Lengina M.A., Dubinets I.D., Korkmazov A.M. Cause-effect factors of rhinosinusitis poliposa development. Rossiyskaya rinologiya = Russian Rhinology, 2023, Vol. 31, no. 2, pp. 124-130. (In Russ.)]
- Коркмазов М.Ю., Ангелович М.С., Ленгина М.А., Белоусов С.Ю. Клинический случай ангиосаркомы решетчатого лабиринта и лобной пазухи, вопросы морфологической верификации диагноза // Вестник оториноларингологии, 2022. Т. 87, № 4. С. 102-106. [Korkmazov M.Yu., Angelovich M.S., Lengina M.A., Belousov S.Yu. Clinical case of angiosarcoma of ethmoidal labyrinth and frontal sinus, issues of morphological verification of diagnosis. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology, 2022, Vol. 87, no. 4, pp. 102-106. (In Russ.)]
- Щетинин С.А., Гизингер О.А., Коркмазов М.Ю. Клинические проявления и дисфункции иммунного статуса у детей с хроническим аденоидитом и методы их коррекции с использованием озонотерапии // Российский иммунологический журнал, 2015. Т. 9, № 3-1. С. 255-257. [Shchetinin S.A., Gisinger O.A., Korkmazov M.Yu. Clinical manifestations and dysfunctions of the immune status in children with chronic adenoiditis and methods of their correction using ozone therapy. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2015, Vol. 9, no. 3-1, pp. 255-257. (In Russ.)]
- Kirby T. Global measles cases up 20% in 2023. Lancet Infect. Dis., 2025, Vol. 25, no. 1, e17. doi: 10.1016/S1473-3099(24)00827-2.
- Montroy J., Yan C., Khan F., Forbes N., Krishnan R., Tunis M., Salvadori M.I. Post-exposure prophylaxis for the prevention of measles: A systematic review. Vaccine, 2025, Vol. 47, 126706. doi: 10.1016/j.vaccine.2025.126706.
- Vittrup D.M., Charabi S., Jensen A., Stensballe L.G. A systematic review and meta-analysis of adverse events following measles-containing vaccines in infants less than 12 months of age. Vaccine, 2025, Vol. 47, 126687. doi: 10.1016/j.vaccine.2024.126687.
Supplementary files
